Holdings
Vanguard Health Care Fund
As of Jul 31, 2026, Vanguard Health Care Fund reported 81 positions worth US$37B. Largest: Eli Lilly and Company, Merck & Company, Inc. and Johnson & Johnson. What it bought and sold, with each filing.
Holdings
- Part of
- Vanguard
- Positions
- 81
- Value as reported
- US$37B
- Holdings as of
- Jul 31, 2026
- Last filed
- Sep 28, 2026
| Company | Shares | Value as reported | % of portfolio | Change | As of |
|---|---|---|---|---|---|
| Eli Lilly and Company NYSE:LLY | 2.86M | US$3.29B | 8.6% | −721K | Jul 31, 2026 |
| Merck & Company, Inc. NYSE:MRK | 16M | US$2.08B | 5.4% | −2.33M | Jul 31, 2026 |
| Johnson & Johnson NYSE:JNJ | 7.19M | US$1.84B | 4.8% | +1.66M | Jul 31, 2026 |
| AstraZeneca PLC LSE:AZN | 10.3M | US$1.75B | 4.6% | +403K | Jul 31, 2026 |
| UnitedHealth Group Incorporated NYSE:UNH | 3.73M | US$1.55B | 4.0% | −165K | Jul 31, 2026 |
| GSK plc LSE:GSK | 44M | US$1.15B | 3.0% | +44,821 | Jul 31, 2026 |
| Edwards Lifesciences Corporation NYSE:EW | 11.4M | US$978M | 2.6% | −2.8M | Jul 31, 2026 |
| Intuitive Surgical, Inc. NASDAQ:ISRG | 2.73M | US$963M | 2.5% | +539K | Jul 31, 2026 |
| CVS Health Corporation NYSE:CVS | 9.21M | US$962M | 2.5% | −546K | Jul 31, 2026 |
| Cencora, Inc. NYSE:COR | 3.03M | US$945M | 2.5% | +549K | Jul 31, 2026 |
| Vertex Pharmaceuticals Incorporated NASDAQ:VRTX | 1.89M | US$902M | 2.4% | +88,223 | Jul 31, 2026 |
| AbbVie Inc. NYSE:ABBV | 3.51M | US$880M | 2.3% | +1.15M | Jul 31, 2026 |
| Danaher Corporation NYSE:DHR | 4.28M | US$834M | 2.2% | −561K | Jul 31, 2026 |
| Regeneron Pharmaceuticals, Inc. NASDAQ:REGN | 1.07M | US$818M | 2.1% | +140K | Jul 31, 2026 |
| Novartis AG SIX:NOVN | 4.66M | US$729M | 1.9% | +615K | Jul 31, 2026 |
| Elevance Health, Inc. NYSE:ELV | 1.86M | US$698M | 1.8% | no change | Jul 31, 2026 |
| argenx SE EURONEXT:ARGX | 694K | US$642M | 1.7% | −403K | Jul 31, 2026 |
| HCA Healthcare, Inc. NYSE:HCA | 1.59M | US$642M | 1.7% | +391K | Jul 31, 2026 |
| Ucb S.A. EURONEXT:UCB | 2.48M | US$637M | 1.7% | +127K | Jul 31, 2026 |
| Boston Scientific Corporation NYSE:BSX | 12.5M | US$583M | 1.5% | −2.6M | Jul 31, 2026 |
| Agilent Technologies, Inc. NYSE:A | 4.12M | US$570M | 1.5% | +296K | Jul 31, 2026 |
| Biogen Inc. NASDAQ:BIIB | 2.75M | US$557M | 1.5% | +219K | Jul 31, 2026 |
| Galderma Group AG SIX:GALD | 2.41M | US$525M | 1.4% | +182K | Jul 31, 2026 |
| Roche Holding Ltd SIX:RO | 1.03M | US$450M | 1.2% | −92,626 | Jul 31, 2026 |
| DexCom, Inc. NASDAQ:DXCM | 5.38M | US$449M | 1.2% | −981K | Jul 31, 2026 |
| Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY | 2.14M | US$439M | 1.2% | +466K | Jul 31, 2026 |
| Cardinal Health, Inc. NYSE:CAH | 1.9M | US$438M | 1.1% | −413K | Jul 31, 2026 |
| Abbott Laboratories NYSE:ABT | 3.72M | US$393M | 1.0% | −5.12M | Jul 31, 2026 |
| Shionogi & Co., Ltd. TSE:4507 | 21.4M | US$387M | 1.0% | +988K | Jul 31, 2026 |
| Centene Corporation NYSE:CNC | 6.15M | US$383M | 1.0% | +4.79M | Jul 31, 2026 |
| Amgen Inc. NASDAQ:AMGN | 985K | US$379M | 0.99% | new | Jul 31, 2026 |
| Otsuka Holdings Co., Ltd. TSE:4578 | 5.42M | US$376M | 0.99% | −784K | Jul 31, 2026 |
| Revolution Medicines, Inc. NASDAQ:RVMD | 1.99M | US$373M | 0.98% | +150K | Jul 31, 2026 |
| United Therapeutics Corporation NASDAQ:UTHR | 719K | US$372M | 0.98% | −104K | Jul 31, 2026 |
| Genmab A/S OMXCOP:GMAB | 1.28M | US$368M | 0.96% | −67,079 | Jul 31, 2026 |
| Daiichi Sankyo Company, Limited TSE:4568 | 22.7M | US$366M | 0.96% | no change | Jul 31, 2026 |
| Medtronic plc. NYSE:MDT | 4.23M | US$361M | 0.95% | no change | Jul 31, 2026 |
| Chugai Pharmaceutical Co., Ltd. TSE:4519 | 8.26M | US$359M | 0.94% | −341K | Jul 31, 2026 |
| Stryker Corporation NYSE:SYK | 1.09M | US$354M | 0.93% | +117K | Jul 31, 2026 |
| Ionis Pharmaceuticals, Inc. NASDAQ:IONS | 6.21M | US$322M | 0.84% | +2.41M | Jul 31, 2026 |
| Incyte Corporation NASDAQ:INCY | 2.39M | US$285M | 0.75% | +20,581 | Jul 31, 2026 |
| Ascendis Pharma A/S NASDAQ:ASND | 1.1M | US$268M | 0.70% | +46,928 | Jul 31, 2026 |
| Thermo Fisher Scientific Inc NYSE:TMO | 459K | US$264M | 0.69% | −287K | Jul 31, 2026 |
| Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 563K | US$263M | 0.69% | +154K | Jul 31, 2026 |
| Cytokinetics, Incorporated NASDAQ:CYTK | 3.34M | US$258M | 0.68% | −141K | Jul 31, 2026 |
| BridgeBio Pharma, Inc. NASDAQ:BBIO | 3.16M | US$253M | 0.66% | +2.18M | Jul 31, 2026 |
| STERIS plc (Ireland) NYSE:STE | 1.1M | US$251M | 0.66% | +8,140 | Jul 31, 2026 |
| Qiagen N.V. NYSE:QGEN | 6.05M | US$250M | 0.66% | −469K | Jul 31, 2026 |
| Eisai Co., Ltd. TSE:4523 | 7.34M | US$221M | 0.58% | no change | Jul 31, 2026 |
| CG Oncology, Inc. NASDAQ:CGON | 2.86M | US$204M | 0.53% | +271K | Jul 31, 2026 |
| Bristol-Myers Squibb Company NYSE:BMY | 3.06M | US$200M | 0.52% | −598K | Jul 31, 2026 |
| Kymera Therapeutics, Inc. NASDAQ:KYMR | 1.8M | US$186M | 0.49% | no change | Jul 31, 2026 |
| Scholar Rock Holding Corporation NASDAQ:SRRK | 3.86M | US$183M | 0.48% | +393K | Jul 31, 2026 |
| Protagonist Therapeutics, Inc. NASDAQ:PTGX | 1.24M | US$170M | 0.45% | −137K | Jul 31, 2026 |
| Dianthus Therapeutics, Inc. NASDAQ:DNTH | 1.5M | US$161M | 0.42% | +259K | Jul 31, 2026 |
| Novo Nordisk A/S Class B OMXCOP:NOVO_B | 3.32M | US$157M | 0.41% | −809K | Jul 31, 2026 |
| PTC Therapeutics, Inc. NASDAQ:PTCT | 2.31M | US$157M | 0.41% | +272K | Jul 31, 2026 |
| Option Care Health, Inc. NASDAQ:OPCH | 6.75M | US$155M | 0.41% | +425K | Jul 31, 2026 |
| ICON plc NASDAQ:ICLR | 934K | US$153M | 0.40% | −604K | Jul 31, 2026 |
| Heartflow, Inc. NASDAQ:HTFL | 5.8M | US$146M | 0.38% | +132K | Jul 31, 2026 |
| Celldex Therapeutics, Inc. NASDAQ:CLDX | 3.78M | US$144M | 0.38% | −495K | Jul 31, 2026 |
| Encompass Health Corporation NYSE:EHC | 1.25M | US$139M | 0.36% | −348K | Jul 31, 2026 |
| Moderna, Inc. NASDAQ:MRNA | 2.35M | US$129M | 0.34% | +350K | Jul 31, 2026 |
| Vaxcyte, Inc. NASDAQ:PCVX | 2.34M | US$127M | 0.33% | −327K | Jul 31, 2026 |
| M3, Inc. TSE:2413 | 9.45M | US$106M | 0.28% | no change | Jul 31, 2026 |
| Inspire Medical Systems, Inc. NYSE:INSP | 2.09M | US$105M | 0.28% | no change | Jul 31, 2026 |
| Alignment Healthcare, Inc. NASDAQ:ALHC | 6.93M | US$103M | 0.27% | +641K | Jul 31, 2026 |
| Arcus Biosciences, Inc. NYSE:RCUS | 3.45M | US$97.1M | 0.25% | no change | Jul 31, 2026 |
| Zenas BioPharma, Inc. NASDAQ:ZBIO | 2.94M | US$92.3M | 0.24% | new | Jul 31, 2026 |
| Immunome, Inc. NASDAQ:IMNM | 3.7M | US$84.3M | 0.22% | +927K | Jul 31, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A SSE:600276 | 9.54M | US$72.5M | 0.19% | −829K | Jul 31, 2026 |
| Dyne Therapeutics, Inc. NASDAQ:DYN | 2.81M | US$70.7M | 0.19% | new | Jul 31, 2026 |
| Zai Lab Ltd. HKEX:9688 | 36.4M | US$66.4M | 0.17% | no change | Jul 31, 2026 |
| Genfleet Therapeutics (Shanghai), Inc. Class H HKEX:2595 | 18.5M | US$65.3M | 0.17% | no change | Jul 31, 2026 |
| Stoke Therapeutics, Inc. NASDAQ:STOK | 2.26M | US$65.2M | 0.17% | +608K | Jul 31, 2026 |
| Duality Biotherapeutics, Inc. HKEX:9606 | 2.77M | US$64.4M | 0.17% | no change | Jul 31, 2026 |
| Pharvaris N.V. NASDAQ:PHVS | 1.17M | US$38M | 0.10% | new | Jul 31, 2026 |
| Kailera Therapeutics, Inc. NASDAQ:KLRA | 2.19M | US$37.1M | 0.10% | +64,664 | Jul 31, 2026 |
| Shandong Weigao Group Medical Polymer Co. Ltd. Class H HKEX:1066 | 77.1M | US$33M | 0.09% | no change | Jul 31, 2026 |
| Aktis Oncology, Inc. NASDAQ:AKTS | 1.46M | US$32.3M | 0.08% | −561K | Jul 31, 2026 |
| Definium Therapeutics, Inc. NASDAQ:DFTX | 741K | US$32.2M | 0.08% | new | Jul 31, 2026 |